The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2019Enhancing the Clinical Utility of Data-Driven Parkinson’s Subtypes with Knowledge Distillation and Visualization
Study Rationale:
Data-driven analytics, such as machine learning methods, have been applied to discover comprehensive Parkinson’s disease (PD) subtypes from observational patient data. However, many... -
LRRK2 Biology Consortium, 2019LRRK2 Activity and Dyskinesia Supplement
Promising Outcomes of Original Grant:
Our preliminary funding supported exploration of the role of striatal LRRK2 in the development of levodopa-induced dyskinesia (LID). We found that inhibiting... -
Research Grant, 2019Mechanistic Characterization of the PINK1-amplifying Compound MTK-458
Study Rationale:
Loss-of-function mutations in components of the PINK1/PRKN pathway lead to early onset Parkinson’s disease. Previous work by our company has shown that our compounds can amplify the... -
Research Grant, 2019Pre-formed Fibril-seeded Synucleinopathy: Impact on Proinflammatory Cytokines and Contralateral Excitotoxicity
Promising Outcomes of Original Grant:
We have successfully characterized the time course and magnitude of alpha-synuclein aggregation and neurodegeneration of the nigrostriatal system following... -
Biomarkers of Protein Handling/Autophagy, Exosomes and Lipid, 2019Measuring Lipids in iPSC-derived Dopamine Neurons to Identify Parkinson’s Biomarkers
Study Rationale:
Changes in lipid metabolism have been strongly associated with Parkinson’s disease (PD). Lipids have the potential to be important biomarkers for PD, but the lack of appropriate tools... -
Research Grant, 2019Biologically Meaningful Modulation of Alpha-synuclein Expression via Clenbuterol
Promising Outcomes of Original Grant:
The drug clenbuterol, a beta-2 adrenoreceptor agonist, has been shown to decrease alpha-synuclein expression and to be neuroprotective in some models. Our results...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.